Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
MTS（株式会社メディカル・トランスレーション・サービス） is a professional medical translation company in Japan. Founded in 1999, it focuses on pharmaceuticals, medical devices, and medicine-related documents. It is closer to a “professional services / language service provider for enterprise use” than a standard SaaS platform.
Its core services include human translation, AI machine translation/post-editing, subtitle translation, audio transcription, QC proofreading, glossary and translation memory creation, layout/desktop publishing, and native-speaker review. It covers a wide range of medical and pharmaceutical scenarios, including clinical trial protocols, CTD, STED, IFU, package inserts, USPI/SmPC, safety documents, GMP/CMC, medical papers, training materials, and website translation. The company says it has more than 700 registered translators, with proofreading handled by reviewers who are separate from the translators.
Pricing is quoted on a per-project basis: Japanese-to-English is priced by the source character count, while English-to-Japanese is priced by the number of English words, with additional fees for layout work, native-speaker review, and other services. After the source files are submitted, a quote is usually provided the same day or the next day. In principle, no rush fees are charged. Payment is by invoice after delivery, with bank transfer from the client. Free trial translations may be available for first-time, large-volume, or long-term projects, but trial translation is not offered for subtitle translation.
Its strengths are its strong industry specialization, mature workflow, and ISO 17100:2015 certification. It can also sign confidentiality agreements, making it suitable for highly sensitive medical and pharmaceutical materials. The dedicated account manager model is also helpful for long-term clients to accumulate terminology and preferences. The drawbacks are that the official website does not disclose specific unit prices; details about the AI translation engine, data isolation, and compliance are not explained; and there is no visible online collaboration platform, permission management, API, or system integration capability. As a result, it is not suitable for self-service procurement or automated invocation in a SaaS-style workflow.
It is suitable for pharmaceutical companies, medical device manufacturers, CROs, hospitals, universities, and organizations that need Japanese-English or multilingual medical translation. Access from mainland China cannot be determined from the crawled text alone, so it is marked as unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on m-t-s.jp official site.
m-t-s.jp is an Japan Translation provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach m-t-s.jp directly.